Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...

Amgen, a global biotechnology leader highlighting profound research and development capabilities and biomanufacturing, showcases its latest achievements in the field of innovative medicines under the ...

Thousand Oaks-based Amgen shared strong third-quarter results on Oct. 30, beating expectations, but all eyes appear to be on the big biotech's future, which includes trial data from its potentially ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

Amgen reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen Inc.'s Q3 earnings may not be a major upside, but new pipeline drugs and potential breakthroughs could drive growth.

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Amgen (NASDAQ: AMGN) Q3 2024 Earnings Call Oct 30, 2024, 4:30 p.m. ET ...